Acadia Pharmaceuticals
ACAD
333 hedge funds and large institutions have $3.58B invested in Acadia Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 126 increasing their positions, 106 reducing their positions, and 32 closing their positions.
81% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 32
31% more call options, than puts
Call options by funds: $34.2M | Put options by funds: $26.1M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
19% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 106
7% more funds holding
Funds holding: 310 → 333 (+23)
2% less capital invested
Capital invested by funds: $3.66B → $3.58B (-$84.3M)
2.07% less ownership
Funds ownership: 101.47% → 99.39% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$56.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$44.5M |
| 3 |
Millennium Management
New York
|
+$33.4M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$31M |
| 5 |
State Street
Boston,
Massachusetts
|
+$25.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$69.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$63.6M |
| 3 |
RI
RTW Investments
New York
|
-$43.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$39.9M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$39.8M |
ACAD Hedge Fund Activity: Q3 2025 in Review
333 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2025, worth a combined $3.58B — down 2.3% from $3.66B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new ACAD positions and 32 closed out — a net gain of 26 holders — while 126 added to existing stakes and 106 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $56.3M. The largest seller was Morgan Stanley, cutting an estimated $69.1M.
- 333 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2025, up from 310 in Q2 2025.
- Funds reported $3.58B of Acadia Pharmaceuticals stock for Q3 2025, down 2.3% quarter-over-quarter.
- 58 funds opened new Acadia Pharmaceuticals positions in Q3 2025 and 32 closed out, a net change of +26 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2025 was Braidwell, an estimated $56.3M added.
- The largest Acadia Pharmaceuticals seller in Q3 2025 was Morgan Stanley, an estimated $69.1M sold.
Based on aggregated 13F filings for Q3 2025.